Antisense ODNs directed against leukemia inhibitory factor (LIF) and cardiotrophin-1 were successful in downregulating angiotensin II-induced cardiac hypertrophy in vitro [40]. The gene discussed is LIF; the disease is cardiac hypertrophy.